Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 11
- DOI:
- 10.3760/cma.j.issn.0366-6999.2010.11.012
- Key Word:
- travoprost;prostaglandin analogue;intraocular pressure;glaucoma
Abstract： Background Travoprost has been widely used for the treatment of patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The aim of this study was to evaluate the intraocular pressure (IOP) lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients.Methods This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy (due to either inadequate efficacy or safety issues) as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. In both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. IOP measurements were performed at the same time of day at the follow-up visits.Results For patients transitioned to travoprost, mean IOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were: latanoprost, (4.3±4.6) mmHg; β-blocker, (6.3±4.0) mmHg; a-agonist, (7.5±4.3) mmHg; topical carbonic anhydrase inhibitors, (8.0±4.9) mmHg. All mean IOP changes from baseline were statistically significant (P <0.001). No treatment-related serious adverse events were reported in this study.Conclusions In patients treated with other hypotensive medications or untreated, the IOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate IOP control. Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension.
- [1]S, Orengo-Nania,T, Landry,M, Von Tress,etc.Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%.[J].2001,132(6).
- [2]A, Alm.Comparative phase III clinical trial of latanoprost and timolol in patients with elevated intraocular pressure.[J].1995,23.
- [3]Carl B. Camras.Comparison of Latanoprost and Timolol in Patients with Ocular Hypertension and Glaucoma: A Six-month, Masked, Multicenter Trial in the United States[J].1996,103(1).
- [4]Flanagan JG,Sigal IA,Ethier CR.Factors influencing optic nerve head biomechanics.[J].2005,46(11).
- [5]Sharif NA,Zinke PW,lconLabs.com,etc.Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist.[J].2001,17(5).
- [6]Hollo G,Vargha P,Kothy P.Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication.[J].2005,21(12).
- [7]Paul R, Lichter.Expectations from clinical trials: results of the Early Manifest Glaucoma Trial.[J].2002,120(10).
- [8]Brandt JD,VanDenburgh AM,Chen K,etc.Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.[J].2001,108(6).
- [9]Peter Watson,Johan Stjernschantz.A Six-month, Randomized, Double-masked Study Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular Hypertension[J].1996,103(1).
- [10]Björn Friström.A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension[J].1996,74(2).
- [11]Gandolfi SA,Cimino L.Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.[J].2003,110(3).
- [12]Barnebey H,Kwok SY.Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting.[J].2000,22(10).
- [13]Griffin BW,Magnino PE,Pang IH,etc.Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization.[J].1998,286(1).
- [14]P A, Netland,T, Landry,E K, Sullivan,etc.Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.[J].2001,132(4).
- [15]Gandolfi S,Simmons ST,Sturm R,etc.Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension.[J].2001,18(3).
- [16]Michael A, Kass,Dale K, Heuer,Eve J, Higginbotham,etc.The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.[J].2002,120(6).
- [17]Jakobsen JE,Cunha-Vaz J,Nordmann JP,etc.Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.[J].2001,10(5).
- [18]Griffin BW,Williams GW,Sharif NA,etc.FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: a pharmacological study.[J].1997,281(2).
- [19]Gary D. Novack,Robert David,Pei-Fei Lee,etc.Effect of Changing Medication Regimens in Glaucoma Patients[J].1988,196(1).
- [20]Williams GW,Sharif NA,Crider JY,etc.Pharmacology of (3H)prostaglandin E1/(3H)prostaglandin E2 and (3H)prostaglandin F2alpha binding to EP3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data.[J].1998,286(2).
- [21]Silver LH,Ratliff M,Fellman RL,etc.Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.[J].2002,109(5).
- [22]Stewart WC,Zimmerman TJ.Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments.[J].2003,19(5).